These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 17261428

  • 1. Impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a large dialysis network.
    Wald R, Tentori F, Tighiouart H, Zager PG, Miskulin DC.
    Am J Kidney Dis; 2007 Feb; 49(2):257-66. PubMed ID: 17261428
    [Abstract] [Full Text] [Related]

  • 2. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD, Alvarez-Ude F, Gil MT, Soriano A, Egea JJ, Millán I, Amoedo ML, Muray S, Carretón MA.
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [Abstract] [Full Text] [Related]

  • 3. Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization?
    Tentori F, Hunt WC, Rohrscheib M, Zhu M, Stidley CA, Servilla K, Miskulin D, Meyer KB, Bedrick EJ, Johnson HK, Zager PG.
    J Am Soc Nephrol; 2007 Aug; 18(8):2377-84. PubMed ID: 17634440
    [Abstract] [Full Text] [Related]

  • 4. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
    Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, Valdivielso JM, Fernández E.
    Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
    [Abstract] [Full Text] [Related]

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 6. Adherence to mineral and bone disorder clinical practice guidelines in chronic kidney disease.
    Panawong W, Chaiyakum A, Pongskul C.
    J Med Assoc Thai; 2011 Oct; 94(10):1175-83. PubMed ID: 22145501
    [Abstract] [Full Text] [Related]

  • 7. Do differences in dialysis prescription impact on KDOQI bone mineral targets? The Pan Thames Renal Audit.
    Davenport A, Gardner C, Delaney M, Pan Thames Renal Audit Group.
    Blood Purif; 2010 Oct; 30(2):111-7. PubMed ID: 20714141
    [Abstract] [Full Text] [Related]

  • 8. [CA-P control in haemodialysis and K/DOQI guidelines].
    Rivera F, Sánchez de la Nieta MD, Echarri R, Anaya S, Carreño A, Vozmediano MC, Alcaide MP.
    Nefrologia; 2006 Oct; 26(3):351-7. PubMed ID: 16892824
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Are CSN and NKF-K/DOQI mineral metabolism guidelines for hemodialysis patients achievable? Results from a provincial renal program.
    Wazny LD, Raymond CB, Lesperance EM, Bernstein KN.
    CANNT J; 2008 Oct; 18(2):36-41, 44-50; quiz 42-3, 51-2. PubMed ID: 18669010
    [Abstract] [Full Text] [Related]

  • 12. Association between C-reactive protein and biomarkers of bone and mineral metabolism in chronic hemodialysis patients: a cross-sectional study.
    Lee CT, Tsai YC, Ng HY, Su Y, Lee WC, Lee LC, Chiou TT, Liao SC, Hsu KT.
    J Ren Nutr; 2009 May; 19(3):220-7. PubMed ID: 19243976
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.
    Mazzaferro S, Pasquali M, Farcomeni A, Vestri AR, Filippini A, Romani AM, Barresi G, Pugliese F.
    Nephrol Dial Transplant; 2008 Jul; 23(7):2319-23. PubMed ID: 18281320
    [Abstract] [Full Text] [Related]

  • 15. Dialysis adequacy and Kidney Disease Outcomes Quality Initiative goals achievement in an Iranian hemodialysis population.
    Malekmakan L, Haghpanah S, Pakfetrat M, Malekmakan A, Alimanesh M, Haghpanah A, Khajedehi P.
    Iran J Kidney Dis; 2010 Jan; 4(1):39-43. PubMed ID: 20081303
    [Abstract] [Full Text] [Related]

  • 16. K/DOQI guidelines for bone metabolism and disease in chronic kidney disease patients: some therapeutic implications.
    Uribarri J, National Kidney Foundation.
    Semin Dial; 2004 Jan; 17(5):349-50. PubMed ID: 15461740
    [Abstract] [Full Text] [Related]

  • 17. Adherence to K/DOQI practice guidelines for bone metabolism and disease.
    Hoy T, Fisher M, Barber B, Borker R, Stolshek B, Goodman W.
    Am J Manag Care; 2007 Nov; 13(11):620-5. PubMed ID: 17988187
    [Abstract] [Full Text] [Related]

  • 18. Quality of care assessment and adherence to the international guidelines considering dialysis, water treatment, and protection against transmission of infections in university hospital-based dialysis units in Cairo, Egypt.
    Ibrahim S.
    Hemodial Int; 2010 Jan; 14(1):61-7. PubMed ID: 19758297
    [Abstract] [Full Text] [Related]

  • 19. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK.
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [Abstract] [Full Text] [Related]

  • 20. Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.
    Tangri N, Wagner M, Griffith JL, Miskulin DC, Hodsman A, Ansell D, Naimark DM.
    Am J Kidney Dis; 2011 Mar; 57(3):415-21. PubMed ID: 21131115
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.